Article info

Download PDFPDF
EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial

Authors

  1. Correspondence to Dr H Bootsma, Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, PO-Box 30.001, Groningen 9700 RB, The Netherlands; h.bootsma{at}umcg.nl
View Full Text

Citation

Moerman RV, Arends S, Meiners PM, et al
EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial

Publication history

  • Received April 6, 2013
  • Revised July 22, 2013
  • Accepted July 27, 2013
  • First published August 12, 2013.
Online issue publication 
April 13, 2016

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.